C: Use with caution if Positive aspects outweigh threats. Animal research present chance and human experiments not readily available or neither animal nor human experiments done.

pentobarbital will lower the level or impact of armodafinil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unfamiliar.

Warning when discontinuing CYP3A4 inducers which are coadministered with hydrocodone; plasma concentrations of hydrocodone may raise and may end up in potentially deadly respiratory despair

Exercise warning when a barbiturate is administered into a nursing girl; tiny quantities of barbiturates are excreted in the milk

pentobarbital will reduce the extent or outcome of levamlodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will reduce the extent or effect of larotrectinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

Contraindicated (one)pentobarbital will reduce the extent or impact of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration. Robust or average CYP3A inducers may reduce cobimetinib systemic publicity by >eighty% and reduce its efficacy.

pentobarbital increases toxicity of methoxyflurane by increasing metabolism. Contraindicated. Elevated metabolism of methoxyflurane to nephrotoxic compounds.

pentobarbital will decrease the extent or result of docetaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unfamiliar.

Contraindicated (1)pentobarbital will reduce the level or result of naloxegol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Use of naloxegol with powerful CYP3A4 inducers just isn't advisable

pentobarbital will lessen the extent or outcome of vincristine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Mysterious.

Observe Carefully (1)pentobarbital check here will decrease the extent or influence of glecaprevir/pibrentasvir by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

Barbiturates can induce hepatic microsomal enzymes leading to enhanced metabolism and lowered anticoagulant reaction of oral anticoagulants (eg, warfarin, acenocoumarol, dicumarol, and phenprocoumon); individuals stabilized on anticoagulant therapy may perhaps demand dosage changes if barbiturates are added to or withdrawn from their dosage routine

With therapeutic doses of TCAs, barbiturates improve metabolism and reduce blood concentrations of TCAs.